🔗 Share this article

An everyday slimming pill may assist people cut their weight by up to 20%, as per a trial that might open doors for millions more people to shed pounds.

How the Drug Works

This medication, called orforglipron, targets the identical GLP-1 pathways as weight loss shots such as Mounjaro and Wegovy. In a trial of over 3,000 adults, one in five people who took the once-a-day tablet for 72 weeks lost at least one-fifth of their total weight.

Slimming injections are transformative, but pill versions represent a holy grail because they are easier to store, share and administer, and are also projected to be cheaper, offering fresh hope for millions trying to reduce weight.

The medication is a GLP-1 stimulant, a class of medication that helps lowering blood sugar readings, delays the digestion of meals and may curb hunger.

Trial Results and Accessibility

The weight loss observed in participants using the pill is not as dramatic as that in users using tirzepatide, but experts believe the oral form will be easier to obtain and user-friendly than injections.

Orforglipron is not yet approved by the US Food and Drug Administration or regulators in other countries. Developers has said it expects substantial demand once the oral treatment is launched.

During the trial, the 3,127 participants were split into groups taking the medication tablets of varying strengths, whereas others took a placebo, for 72 weeks.

All of the patients were diagnosed with excess weight, indicating they had a body mass index reading of 30 or higher, but they did not have diabetes. Patients from multiple nations took part in the study.

Significant Results

Researchers discovered that after the study period users on the lowest dose lost an mean of 7.5% of their weight. Participants on the maximum amount lost an average of 11.2% of their body weight.

Among users taking the strongest tablets, more than half had a reduction of at least 10% of weight, 36% had a reduction of 15% or greater, and almost one-fifth had a drop of 20% or more.

The team said other health metrics additionally improved in people using the medication, including better BP, a reduced waist circumference and a reduction in bad cholesterol.

Frequent side-effects were stomach-related, which were described as mild to moderate.

“Among participants with excess weight, long-term use with orforglipron resulted in notable decreases in body weight than inactive treatment,” the authors noted.

Potential Benefits

Health leaders have hailed slimming drugs as game-changing. But shots involve extra work for health services, so tablet forms might benefit millions more people trying to lose weight.

Separate research indicates slimming jabs could be successful on children starting from age six who have obesity or have type 2 diabetes. But, stomach problems were “significantly more common” among young users taking the drugs.

Experts emphasized that extended follow-up durations in upcoming trials and additional practical analysis were “essential to establish the lasting impacts.”